LLY250117C840000
- 0.01
- 0.000.00%
Eli Lilly and Co Newsroom
Marjorie Taylor Greene Discloses Buys of AMD, Alphabet, Amazon, More
Market Whales and Their Recent Bets on LLY Options
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $970 to $1,146
Eli Lilly Is Maintained at Overweight by Wells Fargo
Eli Lilly Is Maintained at Buy by Citigroup
Eli Lilly Analyst Ratings
Is There An Opportunity With Eli Lilly and Company's (NYSE:LLY) 43% Undervaluation?
Eli Lilly (NYSE:LLY) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
Express News | Eli Lilly : Citigroup Cuts Target Price to $1190 From $1250
Express News | Eli Lilly : Wells Fargo Cuts Target Price to $970 From $1000
Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ
Obesity Drug Developer Metsera Sets Terms for $275M IPO
Akero Therapeutics Stock Doubles on Liver Data -- Barrons.com
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146
This Wegovy User Spent $5,000 on a New Wardrobe After Losing 80 Pounds - and She's Not Alone
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $997
Pfizer Succeeds in Late-stage Trial for Colorectal Cancer Therapy
Novo Nordisk Stock Soars on New Weight-Loss Drug Results -- Barrons.com
Express News | Eli Lilly Shares Down 1.2% Premarket After Rival Novo Nordisk's Amycretin Obesity Drug Shows 22% Weight Loss in Early Trial